New target genes for the peroxisome proliferator-activated receptor- (PPAR ) antitumour activity: Perspectives from the insulin receptor

PPAR Research

Volumn , Issue , 2009, Pages

  Brunetti, Antonio ^a   Foti, Daniela P ^a   Paonessa, Francesco ^a   Chiefari, Eusebio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CCAAT ENHANCER BINDING PROTEIN BETA; CIGLITAZONE; HIGH MOBILITY GROUP A1A PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRANSCRIPTION FACTOR SP1;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; INSULIN RESISTANCE; LIGAND BINDING; LIVER CANCER; MALIGNANT TRANSFORMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PROTEIN PROTEIN INTERACTION;

EID: 68149158269     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/571365     Document Type: Article

References (78)

1. Saltiel A. R., Kahn C. R., Insulin signalling and the regulation of glucose and lipid metabolism Nature 2001 414 6865 799 806
2. Goldfine I. D., The insulin receptor: molecular biology and transmembrane signaling Endocrine Reviews 1987 8 3 235 255
3. Ullrich A., Bell J. R., Chen E. Y., Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes Nature 1985 313 6005 756 761
4. White M. F., Kahn C. R., The insulin signaling system The Journal of Biological Chemistry 1994 269 1 1 4
5. Rosen O. M., Structure and function of insulin receptors Diabetes 1989 38 12 1508 1511
6. Araki E., Shimada F., Uzawa H., Mori M., Ebina Y., Characterization of the promoter region of the human insulin receptor gene: evidence for promoter activity The Journal of Biological Chemistry 1987 262 33 16186 16191
7. Seino S., Seino M., Nishi S., Bell G. I., Structure of the human insulin receptor gene and characterization of its promoter Proceedings of the National Academy of Sciences of the United States of America 1989 86 1 114 118
8. Brunetti A., Foti D. P., Goldfine I. D., Identification of unique nuclear regulatory proteins for the insulin receptor gene, which appear during myocyte and adipocyte differentiation Journal of Clinical Investigation 1993 92 3 1288 1295
9. Jensen M., Hansen B., De Meyts P., Schaeffer L., Urso B., Activation of the insulin receptor by insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses The Journal of Biological Chemistry 2007 282 48 35179 35186
10. De Meyts P., Insulin and its receptor: structure, function and evolution BioEssays 2004 26 12 1351 1362
11. Malumbres M., Barbacid M., To cycle or not to cycle: a critical decision in cancer Nature Reviews Cancer 2001 1 3 222 231
12. Taniguchi C. M., Emanuelli B., Kahn C. R., Critical nodes in signalling pathways: insights into insulin action Nature Reviews Molecular Cell Biology 2006 7 2 85 96
13. Samani A. A., Yakar S., LeRoith D., Brodt P., The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocrine Reviews 2007 28 1 20 47
14. Frasca F., Pandini G., Scalia P., Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells Molecular and Cellular Biology 1999 19 5 3278 3288
15. Denley A., Wallace J. C., Cosgrove L. J., Forbes B. E., The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review Hormone and Metabolic Research 2003 35 11-12 778 785
16. Taylor S. I., Deconstructing type 2 diabetes Cell 1999 97 1 9 12
17. DeFronzo R. A., Simonson D., Ferrannini E., Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus Diabetologia 1982 23 4 313 319
18. Hollenbeck C. B., Chen Y. D. I., Reaven G. M., A comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization Diabetes 1984 33 7 622 626
19. Biddinger S. B., Kahn C. R., From mice to men: insights into the insulin resistance syndromes Annual Review of Physiology 2006 68 123 158
20. Taylor S. I., Lilly lecture: molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene Diabetes 1992 41 11 1473 1490
21. Foti D. P., Chiefari E., Fedele M., Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice Nature Medicine 2005 11 7 765 773
22. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia Nature Reviews Cancer 2008 8 12 915 928
23. Frasca F., Pandini G., Sciacca L., The role of insulin receptors and IGF-I receptors in cancer and other diseases Archives of Physiology and Biochemistry 2008 114 1 23 37
24. Papa V., Pezzino V., Costantino A., Elevated insulin receptor content in human breast cancer Journal of Clinical Investigation 1990 86 5 1503 1510
25. Law J. H., Habibi G., Hu K., Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival Cancer Research 2008 68 24 10238 10246
26. Kalli K. R., Falowo O. I., Bale L. K., Zschunke M. A., Roche P. C., Conover C. A., Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling Endocrinology 2002 143 9 3259 3267
27. Cox M. E., Gleave M. E., Zakikhani M., Insulin receptor expression by human prostate cancers Prostate 2009 69 1 33 40
28. Schiel R., Beltschikow W., Steiner T., Stein G., Diabetes, insulin, and risk of cancer Methods and Findings in Experimental and Clinical Pharmacology 2006 28 3 169 175
29. Giovannucci E., Michaud D., The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas Gastroenterology 2007 132 6 2208 2225
30. Osborne C. K., Bolan G., Monaco M. E., Lippman M. E., Hormone responsive human breast cancer in long term tissue culture: effect of insulin Proceedings of the National Academy of Sciences of the United States of America 1976 73 12 4536 4540 (Pubitemid 8013935)
31. Paonessa F., Foti D. P., Costa V., Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer Cancer Research 2006 66 10 5085 5093
32. Kolb S., Fritsch R., Saur D., Reichert M., Schmid R. M., Schneider G., HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells Cancer Research 2007 67 10 4679 4686
33. Sachdev D., Yee D., Disrupting insulin-like growth factor signaling as a potential cancer therapy Molecular Cancer Therapeutics 2007 6 1 1 12
34. Mamula P. W., McDonald A. R., Brunetti A., Regulating insulin-receptor-gene expression by differentiation and hormones Diabetes Care 1990 13 3 288 301
35. Brunetti A., Manfioletti G., Chiefari E., Goldfine I. D., Foti D. P., Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y) The FASEB Journal 2001 15 2 492 500
36. Foti D. P., Iuliano R., Chiefari E., Brunetti A., A nucleoprotein complex containing Sp1, C/EBP, and HMGI-Y controls human insulin receptor gene transcription Molecular and Cellular Biology 2003 23 8 2720 2732
37. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688
38. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
39. Kliewer S. A., Xu H. E., Lambert M. H., Willson T. M., Peroxisome proliferator-activated receptors: from genes to physiology Recent Progress in Hormone Research 2001 56 239 263
40. Rosen E. D., Sarraf P., Troy A. E., PPAR is required for the differentiation of adipose tissue in vivo and in vitro Molecular Cell 1999 4 4 611 617
41. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W., Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers Proceedings of the National Academy of Sciences of the United States of America 1993 90 6 2160 2164
42. Keller H., Mahfoudi A., Dreyer C., Peroxisome proliferator-activated receptors and lipid metabolism Annals of the New York Academy of Sciences 1993 684 157 173
43. Vidal-Puig A. J., Considine R. V., Jimenez-Linan M., Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids Journal of Clinical Investigation 1997 99 10 2416 2422
44. Allred C. D., Kilgore M. W., Selective activation of PPAR in breast, colon, and lung cancer cell lines Molecular and Cellular Endocrinology 2005 235 1-2 21 29
45. Nunez N. P., Liu H., Meadows G. G., PPAR- ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells Cancer Letters 2006 236 1 133 141
46. Padilla J., Kaur K., Harris S. G., Phipps R. P., PPAR- -mediated regulation of normal and malignant B lineage cells Annals of the New York Academy of Sciences 2000 905 97 109
47. Barak Y., Nelson M. C., Ong E. S., PPAR is required for placental, cardiac, and adipose tissue development Molecular Cell 1999 4 4 585 595
48. Maloney C. A., Rees W. D., Gene-nutrient interactions during fetal development Reproduction 2005 130 4 401 410
49. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease Nature 2000 405 6785 421 424
50. Tan N. S., Michalik L., Desvergne B., Wahli W., Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes Journal of Steroid Biochemistry and Molecular Biology 2005 93 25 99 105
51. Chou F.-S., Wang P.-S., Kulp S., Pinzone J. J., Effects of thiazolidinediones on differentiation, proliferation, and apoptosis Molecular Cancer Research 2007 5 6 523 530
52. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR ) The Journal of Biological Chemistry 1995 270 22 12953 12956
53. Saltiel A. R., Olefsky J. M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 1996 45 12 1661 1669
54. Jiang C., Ting A. T., Seed B., PPAR- agonists inhibit production of monocyte inflammatory cytokines Nature 1998 391 6662 82 86
55. Li M., Pascual G., Glass C. K., Peroxisome proliferator-activated receptor -dependent repression of the inducible nitric oxide synthase gene Molecular and Cellular Biology 2000 20 13 4699 4707
56. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82
57. Yu C., Markan K., Temple K. A., Deplewski D., Brady M. J., Cohen R. N., The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor transcriptional activity and repress 3T3-L1 adipogenesis The Journal of Biological Chemistry 2005 280 14 13600 13605
58. Tontonoz P., Hu E., Spiegelman B. M., Stimulation of adipogenesis in fibroblasts by PPAR 2, a lipid-activated transcription factor Cell 1994 79 7 1147 1156
59. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR Molecular Cell 1998 1 3 465 470
60. Costa V., Foti D. P., Paonessa F., The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor- (PPAR ) and thiazolidinedione- PPAR agonists Endocrine-Related Cancer 2008 15 1 325 335
61. Osborne C. K., Monaco M. E., Lippman M. E., Kahn C. R., Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long term tissue culture Cancer Research 1978 38 1 94 102
62. Milazzo G., Giorgino F., Damante G., Insulin receptor expression and function in human breast cancer cell lines Cancer Research 1992 52 14 3924 3930
63. Farid N. R., Shi Y., Zou M., Molecular basis of thyroid cancer Endocrine Reviews 1994 15 2 202 232
64. Grommes C., Landreth G. E., Heneka M. T., Antineoplastic effects of peroxisome proliferator-activated receptor agonists The Lancet Oncology 2004 5 7 419 429
65. Sugawara A., Uruno A., Kudo M., Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor- via an interaction with Sp1 in vascular smooth muscle cells The Journal of Biological Chemistry 2002 277 12 9676 9683
66. Hong J., Samudio I., Liu S., Abdelrahim M., Safe S., Peroxisome proliferator-activated receptor -dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins Endocrinology 2004 145 12 5774 5785
67. Han S., Ritzenthaler J. D., Rivera H. N., Roman J., Peroxisome proliferator-activated receptor- ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1 American Journal of Physiology 2005 289 3 L419 L428
68. Elstner E., Muller C., Koshizuka K., Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8806 8811
69. Mulholland D. J., Dedhar S., Coetzee G. A., Nelson C. C., Interaction of nuclear receptors with the Wnt/ -catenin/Tcf signaling axis: Wnt you like to know? Endocrine Reviews 2005 26 7 898 915
70. Patel L., Pass I., Coxon P., Downes C. P., Smith S. A., Macphee C. H., Tumor suppressor and anti-inflammatory actions of PPAR agonists are mediated via upregulation of PTEN Current Biology 2001 11 10 764 768
71. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR Cell Cycle 2007 6 13 1539 1548
72. Papageorgiou E., Pitulis N., Msaouel P., Lembessis P., Koutsilieris M., The non-genomic crosstalk between PPAR- ligands and ERK1/2 in cancer cell lines Expert Opinion on Therapeutic Targets 2007 11 8 1071 1085
73. Papageorgiou E., Pitulis N., Manoussakis M., Lembessis P., Koutsilieris M., Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells Molecular Medicine 2008 14 7-8 403 411
74. Hilakivi-Clarke L., Wang C., Kalil M., Riggins R., Pestell R. G., Nutritional modulation of the cell cycle and breast cancer Endocrine-Related Cancer 2004 11 4 603 622
75. Wang C., Fu M., DAmico M., Inhibition of cellular proliferation through I B kinase-independent and peroxisome proliferator-activated receptor -dependent repression of cyclin D1 Molecular and Cellular Biology 2001 21 9 3057 3070
76. Savkur R. S., Miller A. R., Investigational PPAR- agonists for the treatment of type 2 diabetes Expert Opinion on Investigational Drugs 2006 15 7 763 778
77. Govindarajan R., Ratnasinghe L., Simmons D. L., Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes Journal of Clinical Oncology 2007 25 12 1476 1481
78. Ramos-Nino M. E., MacLean C. D., Littenberg B., Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System BMC Medicine 2007 5, article 17 1 7